Replies to post #132779 on Vivos Inc (RDGL)

[kayak_wench]

Absolutely. ISR relies on beads that have to be permanently left in the body or removed. Its application is far more limited. Its novelty is the isotope used, Cesium-131. It has a higher energy and a shorter half-life than than typical brachatherapy isotopes.

Their current 'big' deal is the ability to deliver the product through what they call a simply device (see https://isoray.com/clinicians/products/blu-build/).

Ask yourself how that 'simple' device compares to an everyday syringe. Which do you think your doctor will be more comfortable using?

Cesium 131 has a half-life of 9.7 days with average energy of 30.4 keV energy. The half life means it will be take about 97 days to fully dissipate.

Yi 90 has a half life of 2.7 days with an average energy of 0.935 MeV, that is 935 keV (more than an order of magnitude larger). With the shorter half life it is dissipated in 27 days, but more importantly dissipated enough in hours to make it safe for a patient to be with family (i.e. put your grandkid on your lap). An ISR patient shouldn't do that for weeks.

So if ISR product is so great because its easy to deliver, has a short half life and high energy, it is obvious to be RDGL product is better because it is easier to deliver, has shorter half life and more energy.

9.7 day half-life
Energy level at 30.4 Kev
Faster dose delivery rate. 90% of dose delivered in ~33 days
Detectable in the body for only 97 days